Sanofi

Sanofi appoints two new members to executive committee

Friday, May 3, 2013 12:22 PM

Global healthcare company Sanofi is creating two new units, global commercial operations and global divisions and strategic commercial development, to replace the former global operations unit. Peter Guenter, currently senior vice president, Europe, will be appointed executive vice president of global commercial operations. Pascale Witz, currently president and CEO of medical diagnostics at GE Healthcare, will join Sanofi as executive vice president of global divisions and strategic commercial development. Both Guenter and Witz will join the executive committee.

More... »

FDA fast tracks Sanofi and KaloBios' novel biologic for Pseudomonas aeruginosa

Friday, April 26, 2013 02:31 PM

The FDA has granted Fast Track designation to Sanofi Pasteur and KaloBios Pharmaceuticals’ investigational drug KB001A, an antibody fragment intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa (Pa) in mechanically-ventilated patients.

More... »

High school junior Natalie Ng wins International BioGENEius Challenge

Friday, April 26, 2013 11:42 AM

Natalie Ng, a junior at Monta Vista High School in Cupertino, Calif., won the International BioGENEius Challenge, the premier competition for high school students that recognizes outstanding research in biotechnology. Ng’s research in breast cancer and biomarkers helped her stand out from the 13 other finalists from across the U.S., Canada and Australia competing for the Challenge's top prize, a $7,500 cash award.

More... »

Bourne Partners, Covis Pharma acquire U.S. rights for five drugs from Sanofi

Monday, April 8, 2013 11:34 AM

Covis Pharma, a Switzerland-based specialty pharmaceutical company, has formed an agreement with Sanofi-Aventis and certain affiliates to acquire full commercial rights for Nilandron (nilutamide), Plaquenil (hydroxychloroquine), Rilutek (riluzole), Uroxatral (alfuzosin hydrochloride) and Kayexalate (sodium polystyrene sulfate) in the U.S.  

More... »

Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments

Monday, March 25, 2013 12:24 PM

Global healthcare company Sanofi and biopharmaceutical company Transgene have signed a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgene's therapeutic products.

More... »

INC Research appoints James Taylor as vice president of clinical development

Tuesday, March 19, 2013 08:00 AM

INC Research, a therapeutically focused global CRO, has appointed James Taylor as vice president of clinical development.

More... »

Québec invests in public-private partnership for personalized cancer medicine

Wednesday, February 20, 2013 10:55 AM

The Québec government has invested $10 million in the Personalized Medicine Partnership for Cancer (PMPC), a public-private partnership focused on establishing an integrated approach for the development and implementation of clinical biomarkers and other personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients.

More... »

$262M Pan-European drug discovery platform launched

Friday, February 8, 2013 10:48 AM

The European Lead Factory, a novel platform for innovative drug discovery, was launched Feb. 7 by an international consortium of 30 partners. The partnership, the first of its kind, is supported by the Innovative Medicines Initiative (IMI) and creates opportunities for the discovery of new medicines by providing public partners with an “industry-like” discovery platform to translate cutting-edge academic research into high-quality drug lead molecules on a scale and speed that was not possible previously.

More... »

Prize4Life launches PRO-ACT, largest ALS trials database ever created

Friday, December 7, 2012 10:42 AM

Prize4Life, a nonprofit organization dedicated to accelerating discovery of treatments and a cure for ALS (amyotrophic lateral sclerosis, also known as Lou Gehrig's disease), launched the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

More... »

Selecta, Sanofi to develop antigen-specific immunotherapies for life-threatening allergies

Friday, November 30, 2012 10:55 AM

Selecta Biosciences, a Watertown, Mass.-based clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, has entered into a strategic global collaboration with global healthcare company Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.

More... »